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Cell growth, differentiation, and proliferation are all carefully regulated processes. Disruptions in 
these processes are often associated with malignant tumors. The epidermal growth factor 
receptor (EFGR), part of the ErbB family of receptors, is known to play a pivotal role in 
regulating numerous cell growth processes including morphology, differentiation, proliferation, 
and apoptosis in certain cell types. Overexpression or elevated levels of EGFR activity is 
associated with many different types of cancers. Numerous targeted anti-EGFR therapies have 
been developed, including monoclonal antibodies (mAbs) and small molecule tyrosine kinase 
inhibitors. Apatmers provide an attractive alternative to monoclonal antibodies due to their ease 
of synthesis and lack of immunogenicity.  
 
J18 and E07 are two aptamers which were selected for against EGFR. Due to 2’-fluoro 
pyrimidines modification, E07 was chosen for in vivo applications. E07 was further remodeled to 
a minimal length construct that still retained binding affinity for EGFR. A cell growth assay using 
E07 and the anti-EGFR mAb, Cetuximab, revealed that a much larger dose of aptamer was 
needed to achieve the same level of growth inhibition as Cetuximab. In an effort to improve the 
efficiency of E07, an experiment was designed to improve the Kd of E07 with avidity effects – 
supradditive effects observed upon dimerization or multimerization of monomers. Having been 
observed with peptides, it was hypothesized that nucleic acids might also display such avidity 
effects.  
 
Five dimeric constructs of the minimized E07 (MinE07) aptamer were tested using flow 
cytometry assays on A431 cells. Two variables were also tested: the orientation of the 
monomers in the dimeric construct and the distance separating the two monomers. Constructs 
were assembled in three different schemes. First, DNA organizers containing fluorophores 
(fluorescein) were used to direct formation. In a second strategy, the extensions added to 
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MinE07 directed the formation of the dimer. Lastly, the dimer was created via transcription off of 
an ssDNA template. 
 
FACS data revealed that none of the constructs significantly produced avidity effects. However, 
Construct 3 did inconsistently demonstrate slight avidity effects. Depending on the conditions of 
the A431 cells, the cell surface and subsequent assays can change dramatically. The head-to-
tail orientation proved to be more promising in permitting avidity effects. Because no significant 





The epidermal growth factor receptor (EGFR), a member of the ErbB/HER family of Type I 
transmembrane tyrosine kinase receptors, has been implicated in numerous cancers, including 
breast, lung, and colorectal, and head and neck squamous cell cancers.1-5 In normal physiology, 
ErbB receptors play central roles in the development and growth of tissues by moderating cell 
differentiation and morphology.2 Various growth factors, including the epidermal growth factor, 
serve as ligands to this family of receptors. Upon binding of the ligand, homo- or 
heterodimerization of receptors occurs, leading to autohphosphorylation of tyrosine residues on 
the cytoplasmic domains.4 Two primary downstream signaling pathways are then initiated: the 
Ras signaling cascade and the PI3K signaling cascade.4 These downstream cascades lead to 
cell division and subsequent differentiation and proliferation. In addition, dimerized EGFR can 
also be internalized into early endosomes. From these early endosomes, EGFR can either be 
recycled back to the membrane or degraded after processing.6 
 
Overexpression of ErbB receptors, especially of EGFR, has been shown to cause erroneous 
and uncontrolled cell proliferation, leading to malignant tumors.1 In addition, increased activation 
of EGFR has been linked to decreased apoptosis, increased metastasis, and increased 
angiogenesis, all hallmarks of cancerous cells.2 Thus, anti-EGFR therapy is a major area of 
research for anti-cancer therapeutics. Current anti-EGFR agents include monoclonal antibodies 
against EGFR (Cetuximab) and tyrosine kinase inhibitors (Geftinib).2-3,5 However, there are 
some innate problems with using monoclonal antibodies as drugs: use of a biological system, 
difficulty with chemical modifications, and significant immunogenicity.7 This has complicated 
their use as chemotherapeutics. Similarly, the clinical effectiveness of tyrosine kinase inhibitors 
is limited due to resistance development in cancer cells to these inhibitors as well as a general 




Aptamers are single-stranded oligonucleotides, either of deoxyribonucleic acid or ribonucleic 
acid composition, generated from a combinatorial pool and a stringent selection process, such 
as SELEX, Systematic Evolution of Ligands by Exponential Enrichment, with very high affinity 
towards a specific target.9 This high affinity arises from the unique three-dimensional folding of 
the aptamer, allowing it to interact specifically with its target. Binding affinities generally range in 
the nanomolar to picomolar range, comparable to those of monoclonal antibodies.8 Due to their 
nucleic acid origin, aptamers are more easily synthesized by chemical means or can also be 
enzymatically amplified.10 Furthermore, various chemical modifications can be made that give 
aptamers distinctive properties: labeling with fluorescent or radioactive probes for imaging 
purposes, conjugations to various compounds (siRNA and peptides), and increased stability for 
in vivo applications. 11-13 With many of the advantageous properties of monoclonal antibodies 
but few of their disadvantages, aptamers are a relatively new class of therapeutic agents and a 
potentially promising class of clinical drugs.  
 
J18, an aptamer selected against EGFR by Li et al., was characterized by a Kd of about 7 nM. A 
similar selection with 2’fluoro- pyrimidine modified ribonucleotides was performed, resulting in 
E07, in order to extend aptamer half-life for in vivo applications.14 In order to prevent excessive 
aptamer length upon addition of extensions and chemical modifications, minimization was used 
to produce a construct with the minimal length of aptamer that still retained function: MinE07.15 
A431 cells, a model epidermoid carcinoma cell line, are known to overexpress EGFR and thus, 
serve as the model cell line for studying EGFR and the efficacy of anti-EGFR therapies.16 
Because EGFR is internalized upon ligand-binding and dimerzation, ligands such as anti-EGFR 
aptamers are also internalized.6 Internalization of aptamers allows for possible targeted drug 
delivery and imaging potential. It has been shown that J18 binds to and internalizes into A431 




Comparison of E07 and other anti-EGFR therapeutics reveals that despite E07’s high affinity to 
EGFR, its relatively large Kd prevents it from being clinically useful (unpublished data). Thus, in 
order to increase its efficacy, various dimeric MinE07 constructs were made with the idea that 
through avidity effects, dimerized MinE07 would bind at a higher rate.18 Multivalency effects 
have been shown with polypeptides and antibodies to increase efficacy.19 Avidity effects have 
also been observed in receptor signaling.20-21 It was thus hypothesized that aptamers may also 
display avidity effects upon multimerization due to the similar nature of action of antibodies and 
aptamers. To test whether the dimeric MinE07 constructs have better binding rates, flow 
cytometry was used to assess fluorescence (fluorophores were bound to constructs).  
 
METHODS AND MATERIALS 
Synthesis of Extended MinE07 Aptamers 
MinE07 sequence (minimization data not published) used was: 5’-
GGACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCGGAACCGUCC-3’. 3’ 
hybridization extensions and a 5’ probe extension to the minimized aptamer were made with the 
use of various primers (Table 1). All primers and DNA organizers containing fluorescein (Table 
2) were ordered from IDT (Integrated DNA Technologies, Coralville, IA). MinE07 ssDNA 
template was polymerase chain reaction-amplified (Invitrogen, Carlsbad, CA) to make dsDNA. 
dsDNA constructs were then transcribed using a Durascribe® T7 Transcription Kit with 2’-fluoro 
pyrimidines (Epicentre, Madison, WI) to make modified RNA aptamer constructs. RNA 
constructs were then gel purified using an 8% denaturing polyacrylamide gel, eluted, and 
precipitated. Sequences are listed in Table 3. A dimer version of MinE07, containing the full-
length E07 aptamer, 5 As, and the minimized E07 aptamer, was also ordered from IDT: 5’-
GGACGGTTCCGGCTTTGACATGCTTTTCTACGGCGATTAAATCCGTCCTTTTTGGACGGTT
CCGGCTTTGACATGCTTTTCTACGGCGATTAAATCCGTCCTATAGTGAGTCGTATTATC-3’. 
ssDNA template of this dimer construct was PCR-amplified and transcribed as described above 
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to produce the MinE07.Dimer (see Table 3). All RNA constructs and DNA organizers were 
stored in nuclease-free water (Epicentre) at -20°C until use. MFold was used to verify that 
extensions caused no significant changes in the secondary structure of the minimized 
aptamer.22,23 
 
Primer Name Primer Sequence 
Forward  5’-GATAATACGACTCACTATAGGACGGATTTAATCGCCG-3’ 
Forward.Probe 5’-GATAATACGACTCACTATAGGATCCGGAATCTCCGATCTGGACGGATTTAATCGCCG-3’ 






Table 1: All primers were ordered from IDT. Bolded sequences indicate the T7 polymerase promoter and 
underlined sequences indicate hybridization extensions. 
 
 
DNA Organizer Name DNA Organizer Sequence 
Spacer 3 5’-/56-FAM/CATTTAGGACCAACACAA/iSpC3/CATCACCACTTCTACTTA-3’ 
Spacer 9 5’-/56-FAM/CATTTAGGACCAACACAA/iSp9/CATCACCACTTCTACTTA-3’ 




















Table 3: Sequences of aptamer constructs used. Underlined sequences indicate hybridization arms and 
italicized sequence indicates probe hybridization arm. The bolded sequence is the additional As added 
between the full-length E07 and the minimized E07. 
 
Synthesis of SMCC DNA Organizer 
Two constructs, 5’-/56-FAM/CATTTAGGACCAACACAA/3ThioMC3-D/-3’ and 5’-
CATCACCACTTCTACTTAAAAAAAAAAA/3AmM/-3’ were ordered from IDT. Sulfosuccinimidyl-
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC; Thermo Scientific, Rockford, 
IL) was used to crosslink these two constructs to form a fluorescein-DNA organizer. Sulfo-
SMCC was first resuspended in dimethylformamide (Sigma-Aldrich, St. Louis, MO) to a final 
concentration of 20 µg/µL. 20 µL of 500 µM amine-containing DNA was then reacted with 5 µL 
sulfo-SMCC in PBS to a final concentration of 1X PBS 10% DMF (v/v) at room temperature 
overnight. The malemide-activated DNA was subsequently purified using a G-25 Column 
(Roche, Indianapolis, IN). To reduce the disfulfide bonds, 20 µL of 500 µM thiol-containing DNA 
was reacted with 5 µL of 0.5M TCEP (Thermo Scientific) in PBS and DMF to a final 
concentration of 1X PBS 10% DMV (v/v) at room temperature overnight. The reduced 
sulfhydryl-containing DNA was similarly purified using a G-25 column. Both reactive DNAs were 
then incubated together at room temperature overnight. After the reaction went to completion, 
the SMCC DNA organizer was gel purified using an 8% denaturing polyacrylamide gel, eluted, 
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and precipitated. The final sequence was: 5’-56-FAM/CATTTAGGACCAACACAA-/HS/-SMCC-
/2HN/-AAAAAAAAAAATTCATCTTCACCACTAC-3’. It was stored in nuclease-free water at -
20°C until use. 
 
Formation of Dimer MinE07 Constructs 
Dimer constructs were formed from annealing the extended MinE07 apatmers to either DNA 
organizers or to themselves. Construct 1 was formed from annealing MinE07.A and MinE07.B 
with Spacer 3, 9, or 18. Construct 2 was formed from hybridizing the 3’ extensions of MinE07.B 
and MinE07.C and annealing Probe to the 5’ extension of MinE07.C. Construct 3 was formed 
from annealing MinE07.A and MinE07.B to the SMCC DNA organizer. Construct 4 was formed 
from annealing MinE07.A and MinE07.B to Linker.A and LinkerB.5, B.10, or B.15 (Linker.A 
contained the fluorophore). Construct 5 was the transcribed MinE07.Dimer.  
 
Native Gel Electrophoresis 
Native gel electrophoresis was used to verify the formation of MinE07 dimers. Dimer constructs 
were prepared by mixing equal amounts of extended aptamers with the fluorophore-containing 
DNA organizers. Each solution was then heated to 70°C for 3 minutes and cooled to 25°C at a 
rate of 1°C/sec. 1 µL of 50% glycerol was added to 10 µL of 40 µM dimer constructs and then 
loaded onto an 8% native (non-denaturing) polyacrylamide gel. After gel electrophoresis, the gel 
was stained with SYBRGold (Invitrogen) prior to imaging on a PhosphorImager. 
 
Cell Culturing 
The A431 cell line was purchased from ATCC (American Type Culture Collection, Manassas, 
VA). The cells were maintained at 37°C and 5% CO2 in Dulbecco’s Modified Eagle’s Medium 





Media from A431 cells was first removed, followed by a one-time wash with 10% FBS 
Dulbecco’s Phosphate Buffered Saline (Invitrogen). 1 mL of 0.25% trypsin-EDTA (Invitrogen) 
was then added to trypsinize the cells. After approximately 5 minutes (or upon visual 
confirmation of cell detachment) at 37°C and 5% CO2, the reaction was terminated by the 
addition of 4 mL of 10% FBS DMEM. Approximately 5 x 106 cells, as counted with a 
hemocytometer, were used for each flow cytometry assay. The cells were pelleted and washed 
three times with 100 µL of binding buffer (1X DPBS with 5 mM MgCl2) and resuspended into 
100 µL binding buffer aliquots, one for each reaction in the assay: A431 cells only, each 
aptamer with the fluorophore-containing DNA organizer, and the dimeric construct. Aptamer 
was first prepared by annealing each monomer or dimer to the DNA organizer at 70°C for 3 
minutes and cooling to 25°C at a rate of 1°C/sec. Monomeric or dimeric aptamer constructs 
were added to a final concentration of 100 nM in each 100 µL reaction aliquot. A431 cells were 
incubated with aptamer constructs for 30 minutes. After incubation, cells were once again 
washed three times with 100 µL of binding buffer and resuspended in 300 µL of binding buffer. 
Fluorescence was assayed using a FACSCalibur (Becton Dickinson, San Jose, CA). 10,000 
events were collected for each reaction using BD CellQuest Pro Software. Analysis made use of 
the FLH-1 detector at a voltage of 412 mV without gating. A plot of FSC-H vs. SSC-H was used 
to verify viability of cells. 
 
Competition assays were performed using FACSAria (Becton Dickison) and a FITC-H detector. 
All other conditions were the same. MinE07.A was used to establish the initial baseline that 







RESULTS AND DISCUSSION 
Verification of Dimer MinE07 Constructs 
The native gel (Figure 1) shows the formation of the dimer constructs 1, 2, and 3. Construct 5 
was verified with the use of a 8% denaturing gel (data not shown). Construct 4 showed similar 




Figure 1: 8% native gel. Lanes contain: 1 – 25 bp Ladder (Invitrogen); 2 – MinE07.A annealed to Spacer 
3; 3 – MinE07.A + MinE07.B annealed to Spacer 3 (Construct 1); 4 – MinE07.B annealed to Spacer 3; 5 – 
MinE07.C annealed to Probe; 6 – MinE07.B + MinE07.C annealed to Probe (Construct 2); 7 – MinE07.B 
annealed to SMCC DNA organizer; 8 - MinE07.A + MinE07.B annealed to SMCC DNA organizer 
(Construct 3); 9 – MinE07.A annealed to SMCC DNA organizer. 
Dimer Constructs 

























































   
Avutu 
14 
It is evident that sufficient formation of Constructs 2 and 3 occurs such that enough dimeric 
aptamer constructs would be available during flow cytometry assays to see possible avidity 
effects. Construct 1 and 4, however, may not form enough dimerized construct to significantly 
impact binding and show avidity effects.  
 
Flow Cytometry Analysis: Construct 1 
All three Spacers (3, 9, and 18) were tested to see if affecting the distance between the 
aptamers would have an effect on binding. FACS data (Figure 2) indicates that, regardless of 
the length of the internal spacer, the dimer construct does not show avidity. However, based on 
native gel analysis (Figure 1), avidity may not be evident because only a small percentage of 
the aptamer population incubated with A431 cells formed dimers. In addition, the orientation of 
the aptamers may not allow for binding two EGFR dimers in the correct orientation. MinE07.A 
and MinE07.B are attached in a head-to-head orientation (with their 5’ ends facing the same 
direction). To test whether a head-to-tail orientation, one in which the 5’ ends face in opposite 
directions, subsequent apatmers were made in the head-to-tail orientation. It should also be 
noted that MinE07.B binds stronger to EGFR than MinE07.A as indicated by the greater 
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Figure 2: Fluorescein-bound aptamer construct-mediated binding to A431 cells (ME07 refers to MinE07): 
MinE07.A annealed to DNA organizer Spacer (green line), MinE07.B annealed to Spacer (pink line), and 
MinE07.A and MinE07.B annealed to Spacer (blue line). (A): Pink sequences represent the hybridization 
between MinE07.A and its complement in Spacer; blue sequences indicate the hybridization between 
MinE07.B and its complement in Spacer. Internal spacers (IDT) were 3 carbon, 9 carbon, or 18 carbon 
glycol spacers. (B): FACS data of Construct 1 using Spacer 3. (C): FACS data of Construct 1 using 
Spacer 9. (D): FACS data of Construct 1 using Spacer 18.  
 
A composite of Construct 1 with different internal spacer lengths (Figrue 3) shows no 







flexibility afforded by the DNA organizer Spacer or that Construct 1 did not induce EGFR 
dimerization.  
  
Figure 3: FACS data of Construct 1, comparing the different internal spacers which differed by length. 
ME07 refers to MinE07. 
 
Flow Cytometry Analysis: Construct 2 
Construct 2 was made from hybridizing the 3’ extensions of MinE07.B and MinE07.C together 
such that they dimerized in a head-to-tail orientation (with their 5’ extensions facing opposite 
directions). The fluorphore-containing compound was Probe that hybridized to the 5’ extension 
of MinE07.C. FACS data (Figure 4) reveals that the affinity of MinE07.C for EGFR was greatly 
decreased as indicated by a nearly baseline fluorescence signal. Annealing MinE07.B to 
MinE07.C and Probe did not rescue binding affinity despite a change in the orientation from 
head-to-head to head-to-tail. The three-dimensional structure required for MinE07 to correctly 
bind to EGFR was most likely destroyed with the 5’ and 3’ extensions made to MinE07.C and 









































































































































Figure 4: Fluorescein-bound aptamer construct-mediated binding to A431 cells (ME07 refers to MinE07): 
MinE07.B annealed to DNA organizer Spacer 3 (green line), MinE07.C annealed to Probe (pink line), and 
MinE07.B and MinE07.C, and Probe annealed together (blue line). (A): Blue sequence represents 
MinE07.B; pink sequence indicates MinE07.C; and turquoise sequence denotes Probe. (B): FACS data of 
Construct 2.  
 
Flow Cytometry Analysis: Construct 3 
Construct 3 was formed by annealing MinE07.A and MinE07.B to SMCC DNA organizer. SMCC 








Construct 1 except in the length and composition of the spacer between the hybdridization arms 
of the DNA organizer and orientation, Construct 3 provided the best comparison of orientation 
effects on binding affinity. FACS data (Figure 5) indicated no significant avidity effects from the 
dimer construct. However, a greater rightward shift in fluorescence was observed from 
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Figure 5: Fluorescein-bound aptamer construct-mediated binding to A431 cells (ME07 refers to MinE07): 
MinE07.A annealed to SMCC DNA organizer (green line), MinE07.B annealed to SMCC DNA organizer 
(pink line), and MinE07.B and MinE07.C annealed to SMCC DNA organizer (blue line). (A): Pink 
sequences represent the hybridization between MinE07.A and its complement in SMCC DNA organizer; 
blue sequences indicate the hybridization between MinE07.B and its complement in SMCC DNA 
organizer. (B): FACS data of Construct 3. 
 
As stated above, no significant avidity effects were seen with the dimerized aptamer construct. 
Other FACS data (not shown) did seemingly show slight avidity effects. However, inability to 





significant avidity effects. Later experiments (data not shown) reveal that the state of the cells 
(confluent or in growing stage) and whether FACS is performed with attached cells (bound to 
culturing flasks or wells) or unattached cells (trypsinized cells) make a huge impact upon 
binding affinity of aptamers. The binding affinity of MinE07 is greatly reduced with unattached 
cells and with cells that are either overgrown or confluent (data not shown).  
 
Flow Cytometry Analysis: Construct 4 
Construct 4 was oriented head-to-tail with a variable intra-aptamer distance to observe whether 
spacing between aptamers had an effect on binding of dimeric constructs to EGFR. Construct 1 
had indicated that binding affinity is not affected by intra-aptamer space. This conclusion was 
affirmed by FACS data from Construct 4 using Linker.B.5, B.10, and B.15 (Figure 6). 
 
Annealing MinE07.B to Linker.A did not result in a shift in fluorescence, as expected, since 
Linker.A has no sequence that is complementary to MinE07.B. However, annealing MinE07.A to 
Linker.A, which share complementary sequences, also produced no shift in fluorescence, 
indicating the free arm of Linker.A might be interacting with something else.  Annealing each 
individual aptamer to Linker.A and Linker.B resulted in a very slight shift, similar to that 
observed with MinE07.C and Probe. However, in this construct, the extensions made to MinE07 
did not result in a three-dimernsional structure that reduced the binding affinity of the extended 
aptamer to EGFR since the same extensions that were used in forming the dimeric Constructs 1 
and 3 were used to form Construct 4. Thus, the DNA organizers used to form Construct 4 must 
be responsible for the reduced affinity. No other complimentary regions than those indicated 
(Figure 6A) exist, and thus, there is a good possibility that the large size of the extended 
aptamers annealed to the Linkers (A and B) caused this decrease in binding affinity. Similar to 















































































































































































Figure 6: Fluorescein-bound aptamer construct-mediated binding to A431 cells (ME07 refers to MinE07): 
MinE07.A annealed to Linker.A (green line), MinE07.A annealed to Spacer 3 (pink line), MinE07.B 
annealed to Linker.A (blue line), MinE07.B annealed to Spacer 3 (orange line), MinE07.A annealed to 
Linker.A and Linker.B (dark blue line), MinE07.B annealed to Linker.A and Linker.B (yellow line), and 
MinE07.A and MinE07.B annealed to Linker.A and Linker.B (light blue line). (A): Blue sequence 
represents Linker.A that hybridizes to MinE07.A; pink sequence indicates Linker.B that hybridizes to 
MinE07.B. (B): FACS data of Construct 4. Linker.B is a composite of all Linker.Bs (B.5, B.10, and B.15); 
all showed similar shift in fluorescence (data not shown). 
 
Flow Cytometry Analysis: Construct 5 
To remove any possible monomeric form of the aptamer in the population used to dose A431 








second strand, it was transcribed into its modified RNA form. As mentioned earlier, Construct 5 
contains both the full-length E07 and minimized E07 aptamers. Both have similar binding 
affinities (unpublished data). Given the way in which Construct 5 was made, it resulted in a 
head-to-head orientation (like Construct 1). Also, given that this dimeric construct did not have 
any extensions, no fluorescent molecule could bind to it. Thus, a competition assay was 
performed in which a fluorescent ligand of EGFR (MinE07.A annealed to Spacer 3) was 
competed off using MinE07 and Construct 5. FACS data (Figure 7) reveals that Construct 5 is 
much less effective in competing off MinE07.A annealed to Spacer 3 than MinE07 is. A four-fold 
higher concentration of Construct 5 and MinE07 than MinE07.A annealed to Spacer 3 was also 
used to observe a concentration-dependent shift.  
 
The data implies that the head-to-head orientation is less effective than the head-to-tail 
orientation (as also indicated by the comparison between Constructs 1 and 3). The four-fold 
higher concentrations moved the fluoresnce shift leftward as expected, though it was still not 
































































































Figure 7: Competition assay using aptamer construct-mediated binding to A431 cells (ME07 refers to 
MinE07): MinE07.A annealed to Spacer 18 (green line), MinE07 or MinE07.Dimer competing off 
MinE07.A annealed to Spacer 18 (pink line), and four-fold higher concentration of MinE07 or 
MinE07.Dimer competing off MinE07.A annealed to Spacer 18 (blue line). (A): Red sequence represents 
the 5 As separating MinE07 (to the left) and E07 (to the right. (B): FACS competition data using MinE07. 
(C): FACS competition data using MinE07.Dimer. 
 
Flow Cytometry Analysis: Mutant Minimized Aptamers 
To verify that the sequence of the extended aptamers is responsible for the shifts in 






were extended using the same 3’ extensions as those used for MinE07.A and MinE07.B (Table 
3). The mutant constructs were assayed by annealing the mutant aptamers to Spacer 18 DNA 
organizer (same form as Construct 1). FACS data (Figure 8) proved that it was indeed the 
aptamer sequence that mediated binding to EGFR and the subsequent shift in fluorescence. 
  
Figure 8: Fluorescein-bound mutant aptamer construct-mediated binding to A431 cells (ME07 refers to 
MinE07): MinE07.MutA annealed to Spacer 18 (green line) and MinE07.MutA and MinE07.MutB 
annealed to Spacer 18 (pink line). FACS data of mutant aptamers using Spacer 18 (similar formation as 
observed in Construct 1 (Figure 2A).  
 
The mutant aptamer assay was essentially a proof-of-principle used to verify the results of the 
other FACS assays.  
 
Comparison of Dimer Constructs 
The dimer constructs used in this experiment were oriented either head-to-head (with 5’ ends 
facing the same direction) or head-to-tail (with 5’ ends facing in opposite directions): Constructs 
1 and 5 were oriented head-to-head and Constructs 2, 3, and 4 were oriented head-to-tail. The 
head-to-tail orientation seems to have provided the best possibility for avidity effects (as 
suggested by Construct 3). Considering that EGFRs dimerize in a head-to-tail orientation, 
having aptamers in a head-to-tail orientation would facilitate EGFR dimerization.25-26 Another 
variable that was studied was the spacing between the aptamers (by varying the distance 
between the hybridization arm sequences) to see if intra-aptamer distance affected binding 
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affinity to two EGFRs. Constructs 1 and 4 indicate that the intra-aptamer distance does not 
significantly affect binding affinity. Nonetheless, no definite conclusions can be drawn about the 
spacing of EGFRs on the cell surface from this experiment. Since no avidity effects were clearly 
observed, dimerization of EGFR may not have occurred and thus, intra-aptamer distance may 
not have made a significant difference. Complicating the matter, however, is the fact that more 
than 40% of EGFRs exist as dimers prior to stimulation by ligand.26 Pull-down experiments or 
studying downstream protein activity may reveal whether EGFR dimerization was induced by 
dimer constructs or not.27-29 
 
It may also have been interesting to study the affect of dimerization on internalization efficiency 
of anti-EGFR aptamers.30 Approximately 15% of E07 that is bound to EGFR is also internalized 
(unpublished data). It is possible that more or less of the Constructs were internalized due to 
dimerization. A nuclease digestion treatement (as with Riboshredder) would have indicated 
internalization efficiency.17,31 Cell microscopy would have also revealed whether dimeric 
constructs internalized better than monomeric constructs.32-34 
 
Although no avidity was seen with any of the constructs used, Construct 3 did provide some 
evidence that avidity is possible under certain conditions. Increasing the distance between the 
aptamers (by increasing the length of an internal spacer or the distance between the 
hybridization arm sequences) may affect binding affinity once avidity can be consistently 
reproduced. Also, the EGFR pathway in A431 cells (which overexpress EGFR) is known to be 
different than in cells expressing EGFR at normal levels.33 However, given that cancerous cells 
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